Kappos L, Traboulsee A, Li DKB, Bar-Or A, et al. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol 2023 Oct 31. doi: 10.1007/s00415-023-11943.
PMID: 37906326